IGX — Intelgenx Technologies Share News
0.000.00%
Last trade - 00:00- CA$41.92m
- CA$62.83m
- $1.04m
Brief: Intelgenx Technologies Q1 Loss Per Share C$0.03
Clinical trials, drug launches, approvals likely to be hit by coronavirus - William Blair
Brief: IntelGenx Announces Pricing Of Equity Offering
Brief: Intelgenx Enters Animal Health Market By Signing Feasibility Agreement For Vetafilm Platform
Brief: Intelgenx Technologies - Plans To Offer Units For Proceeds Between C$4 Mln-C$10 Mln
Brief: Intelgenx Technologies Corp Says Net Comprehensive Loss For 3-Month Period Ended Sept. 30 Was $2.9 Mln
Brief: Intelgenx Technologies Initiates Scale-Up Work For Cannabis-Infused Versafilm Product
Brief: Intelgenx Announces FDA’S Acceptance Of Resubmitted Rizaport New Drug Application
Brief: Intelgenx Receives Positive DSMB Recommendation For Montelukast VersaFilm Phase 2A Trial
Brief: Intelgenx Announces Resubmission Of Rizaport New Drug Application
Brief: Intelgenx Qtrly Revenue Was $197,000
Brief: Intelgenx Receives First Shipment Of Cannabis Extract From Tilray For Production Of Cannabis-Infused Oral Film
Brief: IntelGenx Reports First Quarter 2019 Financial Results
Brief: Intelgenx Appoints André Godin As President And Chief Financial Officer
Brief: Intelgenx, Aquestive Therapeutics Enter Collaboration Agreement For Tadalafil
Brief: Intelgenx Announces Issuance Of Second U.S. Patent For Topical Oral Film Technology
Brief: Intelgenx Files Non-Provisional U.S. Patent Application For Oil-Based Active Ingredients
Brief: IntelGenx Receives Complete Response Letter From FDA For Rizaport NDA
Brief: Biodelivery Sciences Says On March 1, Bdsi Filed Complaint For Patent Infringement In Delaware